Observational studyJournal of patient-reported outcomes2025
Quality of life and climacteric symptoms in women with endometrial cancer: examining the impact of lower limb lymphedema.
Observational study in Journal of patient-reported outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endometrial cancer therapy in 2026.Current opinion in obstetrics & gynecology · 2026Review
- Research progress on discharge readiness service practices for patients undergoing endometrial cancer surgery.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWomen undergoing treatment for endometrial cancer (EC) often experience climacteric-like symptoms, and some may develop lower limb lymphedema (LLL). LLL can significantly impact women's quality of life (QoL) and exacerbate climacteric symptoms. In this study, we investigated the prevalence of LLL and explored the differences in climacteric symptoms and QoL between women with and without LLL.
methodsA cross-sectional, observational, and comparative study design was employed. Clinical data for 105 women diagnosed with EC were gathered, encompassing demographic details, LLL, climacteric symptoms, and QoL. Instruments used included a demographic-disease survey, the Gynecological Cancer Lymphedema Questionnaire, the Greene Climacteric Scale, and EORTC QLQ-C30 and QLQ-EN24 questionnaires. Descriptive statistics and independent-sample t-tests were utilized for data analysis.
resultsIn this study, 39% of women with EC experienced LLL, with primary symptoms being aching, heaviness, and swelling. Women with LLL also had significantly more severe climacteric symptoms, including anxiety, depression, and vasomotor issues, and they reported poorer physical, role, emotional, cognitive, and social functioning. Additionally, they faced increased fatigue, pain, dyspnea, and more severe specific symptoms like lymphedema, urological and gastrointestinal issues, body image concerns, back/pelvic pain, and hair loss compared to those without LLL.
conclusionThe findings of this study enhance understanding of the impact of LLL on climacteric symptoms and QoL in women with EC. Health-care professionals, when advising treatment for EC, should inform women about the likelihood of LLL and assist in early management of its symptoms during and after EC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.